Project description
Minimising allergic reactions to intravenous immunotherapies with new biosafety testing
Drug development proceeds along a regulated pathway from innovation and research to preclinical and clinical trials to review by national authorities. Many drugs do not make it through clinical trials due to unpredicted adverse side effects in people. Others make it through, despite the side effects, when these are deemed of low enough risk or incidence. For many therapies administered intravenously, infusion reactions (IRs) are common, particularly among immunotherapeutics. Even though these can be severe and even life-threatening, assaying for allergic IRs before a drug gets to clinical phases is challenging because relevant biomarkers or animal models are scarce. EU funding of the Biosafety project is building capacity at Hungary's Semmelweis University with the goal of addressing this problem to enhance the safety of immunotherapeutics for patients who need them.
Fields of science
Programme(s)
- H2020-EU.4.b. - Twinning of research institutions Main Programme
Topic(s)
Funding Scheme
CSA - Coordination and support actionCoordinator
1085 Budapest
Hungary
See on map
Participants (5)
2333 ZA Leiden
See on map
53359 Rheinbach
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2573 HT 'S-gravenhage
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
84036 Landshut
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.